Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay has maintained a Buy rating on Centessa Pharmaceuticals and raised the price target from $20 to $24.
September 11, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has reaffirmed its Buy rating on Centessa Pharmaceuticals and increased the price target from $20 to $24, indicating confidence in the company's future performance.
The increase in the price target from $20 to $24 by Guggenheim suggests a positive outlook on Centessa Pharmaceuticals' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100